127 related articles for article (PubMed ID: 29518282)
21. Biopathological Significance of Early-Phase Amyloid Imaging in the Spectrum of Alzheimer's Disease.
Bunai T; Kakimoto A; Yoshikawa E; Terada T; Ouchi Y
J Alzheimers Dis; 2019; 69(2):529-538. PubMed ID: 31104023
[TBL] [Abstract][Full Text] [Related]
22. Imaging Biomarkers of Alzheimer Disease in Multiple Sclerosis.
Zeydan B; Lowe VJ; Reichard RR; Przybelski SA; Lesnick TG; Schwarz CG; Senjem ML; Gunter JL; Parisi JE; Machulda MM; Vemuri P; Mielke MM; Knopman DS; Petersen RC; Jack CR; Kantarci OH; Kantarci K
Ann Neurol; 2020 Apr; 87(4):556-567. PubMed ID: 31970802
[TBL] [Abstract][Full Text] [Related]
23. Potential Clinical Value of Multiparametric PET in the Prediction of Alzheimer's Disease Progression.
Chen X; Zhou Y; Wang R; Cao H; Reid S; Gao R; Han D;
PLoS One; 2016; 11(5):e0154406. PubMed ID: 27183116
[TBL] [Abstract][Full Text] [Related]
24. Using positron emission tomography and florbetapir F18 to image cortical amyloid in patients with mild cognitive impairment or dementia due to Alzheimer disease.
Fleisher AS; Chen K; Liu X; Roontiva A; Thiyyagura P; Ayutyanont N; Joshi AD; Clark CM; Mintun MA; Pontecorvo MJ; Doraiswamy PM; Johnson KA; Skovronsky DM; Reiman EM
Arch Neurol; 2011 Nov; 68(11):1404-11. PubMed ID: 21747008
[TBL] [Abstract][Full Text] [Related]
25. Regional metabolic patterns in mild cognitive impairment and Alzheimer's disease: A 1H MRS study.
Kantarci K; Jack CR; Xu YC; Campeau NG; O'Brien PC; Smith GE; Ivnik RJ; Boeve BF; Kokmen E; Tangalos EG; Petersen RC
Neurology; 2000 Jul; 55(2):210-7. PubMed ID: 10908893
[TBL] [Abstract][Full Text] [Related]
26. Amyloid burden and metabolic function in early-onset Alzheimer's disease: parietal lobe involvement.
Ossenkoppele R; Zwan MD; Tolboom N; van Assema DM; Adriaanse SF; Kloet RW; Boellaard R; Windhorst AD; Barkhof F; Lammertsma AA; Scheltens P; van der Flier WM; van Berckel BN
Brain; 2012 Jul; 135(Pt 7):2115-25. PubMed ID: 22556189
[TBL] [Abstract][Full Text] [Related]
27. Longitudinal imaging of Alzheimer pathology using [11C]PIB, [18F]FDDNP and [18F]FDG PET.
Ossenkoppele R; Tolboom N; Foster-Dingley JC; Adriaanse SF; Boellaard R; Yaqub M; Windhorst AD; Barkhof F; Lammertsma AA; Scheltens P; van der Flier WM; van Berckel BN
Eur J Nucl Med Mol Imaging; 2012 Jun; 39(6):990-1000. PubMed ID: 22441582
[TBL] [Abstract][Full Text] [Related]
28. Association of short-term cognitive decline and MCI-to-AD dementia conversion with CSF, MRI, amyloid- and
Ottoy J; Niemantsverdriet E; Verhaeghe J; De Roeck E; Struyfs H; Somers C; Wyffels L; Ceyssens S; Van Mossevelde S; Van den Bossche T; Van Broeckhoven C; Ribbens A; Bjerke M; Stroobants S; Engelborghs S; Staelens S
Neuroimage Clin; 2019; 22():101771. PubMed ID: 30927601
[TBL] [Abstract][Full Text] [Related]
29. Pittsburgh compound B (11C-PIB) and fluorodeoxyglucose (18 F-FDG) PET in patients with Alzheimer disease, mild cognitive impairment, and healthy controls.
Devanand DP; Mikhno A; Pelton GH; Cuasay K; Pradhaban G; Dileep Kumar JS; Upton N; Lai R; Gunn RN; Libri V; Liu X; van Heertum R; Mann JJ; Parsey RV
J Geriatr Psychiatry Neurol; 2010 Sep; 23(3):185-98. PubMed ID: 20430977
[TBL] [Abstract][Full Text] [Related]
30. Diagnostic role of 11C-Pittsburgh compound B retention patterns and glucose metabolism by fluorine-18-fluorodeoxyglucose PET/CT in amnestic and nonamnestic mild cognitive impairment patients.
Jiménez-Bonilla JF; Banzo I; De Arcocha-Torres M; Quirce R; Martínez-Rodríguez I; Lavado-Pérez C; Bravo-Ferrer Z; Rodríguez-Rodríguez E; Sánchez-Juan P; Carril JM
Nucl Med Commun; 2016 Nov; 37(11):1189-96. PubMed ID: 27341411
[TBL] [Abstract][Full Text] [Related]
31. Alzheimer's disease neurodegenerative biomarkers are associated with decreased cognitive function but not β-amyloid in cognitively normal older individuals.
Wirth M; Madison CM; Rabinovici GD; Oh H; Landau SM; Jagust WJ
J Neurosci; 2013 Mar; 33(13):5553-63. PubMed ID: 23536070
[TBL] [Abstract][Full Text] [Related]
32. Comparison of 18F-FDG and PiB PET in cognitive impairment.
Lowe VJ; Kemp BJ; Jack CR; Senjem M; Weigand S; Shiung M; Smith G; Knopman D; Boeve B; Mullan B; Petersen RC
J Nucl Med; 2009 Jun; 50(6):878-86. PubMed ID: 19443597
[TBL] [Abstract][Full Text] [Related]
33. The correlation of neuropsychological evaluation with 11C-PiB and 18F-FC119S amyloid PET in mild cognitive impairment and Alzheimer disease.
Park SY; Byun BH; Kim BI; Lim SM; Ko IO; Lee KC; Kim KM; Kim YK; Lee JY; Bu SH; Kim JH; Chi DY; Ha JH
Medicine (Baltimore); 2020 Apr; 99(16):e19620. PubMed ID: 32311931
[TBL] [Abstract][Full Text] [Related]
34. Visual Versus Fully Automated Analyses of 18F-FDG and Amyloid PET for Prediction of Dementia Due to Alzheimer Disease in Mild Cognitive Impairment.
Grimmer T; Wutz C; Alexopoulos P; Drzezga A; Förster S; Förstl H; Goldhardt O; Ortner M; Sorg C; Kurz A
J Nucl Med; 2016 Feb; 57(2):204-7. PubMed ID: 26585056
[TBL] [Abstract][Full Text] [Related]
35. Comparison of Early-Phase 11C-Deuterium-l-Deprenyl and 11C-Pittsburgh Compound B PET for Assessing Brain Perfusion in Alzheimer Disease.
Rodriguez-Vieitez E; Carter SF; Chiotis K; Saint-Aubert L; Leuzy A; Schöll M; Almkvist O; Wall A; Långström B; Nordberg A
J Nucl Med; 2016 Jul; 57(7):1071-7. PubMed ID: 26912447
[TBL] [Abstract][Full Text] [Related]
36. A Cross-Validation of FDG- and Amyloid-PET Biomarkers in Mild Cognitive Impairment for the Risk Prediction to Dementia due to Alzheimer's Disease in a Clinical Setting.
Iaccarino L; Chiotis K; Alongi P; Almkvist O; Wall A; Cerami C; Bettinardi V; Gianolli L; Nordberg A; Perani D
J Alzheimers Dis; 2017; 59(2):603-614. PubMed ID: 28671117
[TBL] [Abstract][Full Text] [Related]
37. Associations between Alzheimer disease biomarkers, neurodegeneration, and cognition in cognitively normal older people.
Wirth M; Villeneuve S; Haase CM; Madison CM; Oh H; Landau SM; Rabinovici GD; Jagust WJ
JAMA Neurol; 2013 Dec; 70(12):1512-9. PubMed ID: 24166579
[TBL] [Abstract][Full Text] [Related]
38. Association Between Amyloid and Tau Accumulation in Young Adults With Autosomal Dominant Alzheimer Disease.
Quiroz YT; Sperling RA; Norton DJ; Baena A; Arboleda-Velasquez JF; Cosio D; Schultz A; Lapoint M; Guzman-Velez E; Miller JB; Kim LA; Chen K; Tariot PN; Lopera F; Reiman EM; Johnson KA
JAMA Neurol; 2018 May; 75(5):548-556. PubMed ID: 29435558
[TBL] [Abstract][Full Text] [Related]
39. Age and neurodegeneration imaging biomarkers in persons with Alzheimer disease dementia.
Knopman DS; Jack CR; Wiste HJ; Weigand SD; Vemuri P; Lowe VJ; Kantarci K; Gunter JL; Senjem ML; Mielke MM; Machulda MM; Roberts RO; Boeve BF; Jones DT; Petersen RC
Neurology; 2016 Aug; 87(7):691-8. PubMed ID: 27421543
[TBL] [Abstract][Full Text] [Related]
40. Consideration of optimal time window for Pittsburgh compound B PET summed uptake measurements.
McNamee RL; Yee SH; Price JC; Klunk WE; Rosario B; Weissfeld L; Ziolko S; Berginc M; Lopresti B; Dekosky S; Mathis CA
J Nucl Med; 2009 Mar; 50(3):348-55. PubMed ID: 19223409
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
